JP2014518280A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518280A5
JP2014518280A5 JP2014519227A JP2014519227A JP2014518280A5 JP 2014518280 A5 JP2014518280 A5 JP 2014518280A5 JP 2014519227 A JP2014519227 A JP 2014519227A JP 2014519227 A JP2014519227 A JP 2014519227A JP 2014518280 A5 JP2014518280 A5 JP 2014518280A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
insomnia
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014519227A
Other languages
English (en)
Japanese (ja)
Other versions
JP6050813B2 (ja
JP2014518280A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/045254 external-priority patent/WO2013009517A1/en
Publication of JP2014518280A publication Critical patent/JP2014518280A/ja
Publication of JP2014518280A5 publication Critical patent/JP2014518280A5/ja
Application granted granted Critical
Publication of JP6050813B2 publication Critical patent/JP6050813B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014519227A 2011-07-08 2012-07-02 二重作用H1インバースアゴニスト/5−HT2Aアンタゴニストとしての(チエノ[2,3−b][1,5]ベンゾオキサゼピン−4−イル)ピペラジン−1−イル化合物 Active JP6050813B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161505685P 2011-07-08 2011-07-08
US61/505,685 2011-07-08
PCT/US2012/045254 WO2013009517A1 (en) 2011-07-08 2012-07-02 (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

Publications (3)

Publication Number Publication Date
JP2014518280A JP2014518280A (ja) 2014-07-28
JP2014518280A5 true JP2014518280A5 (enExample) 2015-08-20
JP6050813B2 JP6050813B2 (ja) 2016-12-21

Family

ID=46513872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014519227A Active JP6050813B2 (ja) 2011-07-08 2012-07-02 二重作用H1インバースアゴニスト/5−HT2Aアンタゴニストとしての(チエノ[2,3−b][1,5]ベンゾオキサゼピン−4−イル)ピペラジン−1−イル化合物

Country Status (22)

Country Link
US (1) US9481688B2 (enExample)
EP (1) EP2729474B1 (enExample)
JP (1) JP6050813B2 (enExample)
KR (1) KR101582429B1 (enExample)
CN (1) CN103703008B (enExample)
AU (1) AU2012283035B2 (enExample)
BR (1) BR112014000379A2 (enExample)
CA (1) CA2840217C (enExample)
DK (1) DK2729474T3 (enExample)
EA (1) EA023460B1 (enExample)
ES (1) ES2665035T3 (enExample)
HR (1) HRP20180475T1 (enExample)
HU (1) HUE037649T2 (enExample)
IN (1) IN2014MN00144A (enExample)
LT (1) LT2729474T (enExample)
MX (1) MX341132B (enExample)
NO (1) NO2729474T3 (enExample)
PL (1) PL2729474T3 (enExample)
PT (1) PT2729474T (enExample)
RS (1) RS57207B1 (enExample)
SI (1) SI2729474T1 (enExample)
WO (1) WO2013009517A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2943498T3 (pl) * 2013-01-14 2018-01-31 Lilly Co Eli Związki (tieno[2,3-b][1,5]benzoksazepin-4-ylo)piperazyn-1-ylowe jako odwrotni agoniści h1 / antagoniści 5-ht2a o podwójnej aktywności
TW201625644A (zh) 2014-04-29 2016-07-16 美國禮來大藥廠 作為選擇性5-HTA反向促效劑之(噻吩并[2,3-b][1,5]苯并氧氮呯-4-基)哌嗪-1-基化合物
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN108371660B (zh) * 2017-12-14 2020-03-10 五邑大学 一种四氢环戊二烯并吡咯化合物及其衍生物的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
AU775299B2 (en) * 1999-09-29 2004-07-29 Eli Lilly And Company Piperidine derivatives as reuptake inhibitors
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
US7807828B2 (en) * 2005-08-11 2010-10-05 Hypnion, Inc. Olanzapine analogs and methods of use thereof
BRPI0808828A8 (pt) * 2007-03-15 2017-11-28 Aryx Therapeutics Inc Compostos de dibenzo[b,f][1,4]oxazapina
JP6106361B2 (ja) * 2008-05-27 2017-03-29 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 睡眠障害および他の障害のための方法および組成物
GB0910009D0 (en) * 2009-06-10 2009-07-22 Glaxo Group Ltd Novel compounds
AR084867A1 (es) * 2011-02-07 2013-07-10 Lilly Co Eli Compuestos de acido [(5h-pirrolo[2,1-c][1,4]benzodiazepin-11-il)piperazin-1-il]-2,2-dimetilpropanoico sustituido como antagonistas de 5-ht/agonistas inversos de actividad dual
AU2012300451B2 (en) * 2011-08-30 2016-10-13 Eli Lilly And Company (thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity H1 inverse agonists/5-HT 2A antagonists

Similar Documents

Publication Publication Date Title
JP2013525444A5 (enExample)
JP2013014622A5 (enExample)
JP2016518337A5 (enExample)
JP2015501783A5 (enExample)
JP2014507446A5 (enExample)
JP2013519675A5 (enExample)
JP2012255026A5 (enExample)
JP2013509429A5 (enExample)
JP2012193216A5 (enExample)
ME02910B (me) Spojevi tetrahidropirolotiazina
JP2017537066A5 (enExample)
JP2011105738A5 (enExample)
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
JP2013532687A5 (enExample)
JP2013522326A5 (enExample)
PL2771329T3 (pl) Nowe związki di-podstawione 3,4-diamino-3-cyklobuteno- 1,2-dionu do zastosowania w leczeniu patologii, w których pośredniczą chemokiny
HRP20171824T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A
JP2012519182A5 (enExample)
JP2015533163A5 (enExample)
JP2015516419A5 (enExample)
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MX342153B (es) Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio.
WO2015107536A3 (en) Fixed dose combination comprising linagliptin and metformin hci
JP2016532632A5 (enExample)
JP2014518280A5 (enExample)